Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01845493 · ClinicalTrials.gov registry record · Phase 1
Sulforaphane Supplementation in Atopic Asthmatics
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01845493 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 16 participants.
The verdict
NCT01845493, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The investigators will perform a pilot study of daily treatment with oral sulforaphane (SFN) for 3 days to determine if Nuclear factor (erythroid-derived 2)-like 2 (NRF2) induction is possible with this supplementation regimen in individuals with allergic asthma.
Interventions
- DIETARY_SUPPLEMENT Alpha Sprout Homogenate
- DIETARY_SUPPLEMENT Sulforaphane Homogenate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01845493
The ClinicalTrials.gov registry entry for NCT01845493 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alpha Sprout Homogenate is the first listed.
NCT01845493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01845493 about?
NCT01845493 is a clinical study titled "Sulforaphane Supplementation in Atopic Asthmatics". The investigators will perform a pilot study of daily treatment with oral sulforaphane (SFN) for 3 days to determine if Nuclear factor (erythroid-derived 2)-like 2 (NRF2) induction is possible with this supplementation regimen in individuals with allergic asthma.
What is the current status of trial NCT01845493?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2013-04. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01845493?
The interventions under investigation include: Alpha Sprout Homogenate (DIETARY_SUPPLEMENT), Sulforaphane Homogenate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01845493?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.